# RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

> **NCT07735624** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 16 (estimated)

## Conditions studied

- Early Rectal Cancer
- Stage I Rectal Cancer
- Microsatellite Stable Rectal Carcinoma

## Interventions

- **DRUG:** Botensilimab
- **DRUG:** Balstilimab

## Key facts

- **NCT ID:** NCT07735624
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2027-01-01
- **Final completion:** 2032-12-31
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-08-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07735624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07735624, "RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07735624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*